ReviewJournal of neural transmission (Vienna, Austria : 1996)2026
Chronic schizophrenia versus Alzheimer's disease: neuroimaging perspectives on the late-life course of schizophrenia.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aging in Schizophrenia: Clinical, Biological, and Psychosocial Perspectives.Geriatrics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia (SCZ) is a chronic mental disorder that typically starts in early adulthood. It is characterised by structural brain abnormalities that occur early in the course of the disease, such as changes in the synapses and alterations in the brain white matter, which consequently progress to brain atrophy in several regions of the brain, as well as white matter lesions. On the other hand, epidemiological evidence indicates improved survival and increased life expectancy among patients with SCZ, largely due to advances in diagnosis and medication management, resulting in a growing number of individuals reaching older age. In addition, several studies have shown accelerated aging and an increased risk of cognitive decline in these patients. Consequently, the healthcare system faces a growing challenge: older adults with chronic SCZ who are at increased risk of dementia (particularly Alzheimer-type dementia). Notably, many individuals with chronic SCZ have several modifiable risk factors for dementia, including obesity, diabetes, elevated low-density lipoprotein cholesterol (LDL), metabolic syndrome, physical inactivity, smoking, and social isolation which may result from a combination of long-term antipsychotic medication, lifestyle factors, and medical comorbidities. These factors overlap substantially with established risk factors for Alzheimer's disease (AD) and may contribute to increased vulnerability to cognitive decline and dementia in later life. The clinical presentation of older adults with chronic SCZ who develop progressive cognitive and functional decline may closely resemble AD, owing to overlapping features such as memory impairment, social withdrawal, psychomotor slowing, and gait disturbances associated with vascular and metabolic comorbidities. Distinguishing these conditions represents a major diagnostic challenge for cognitive neurologists and psychogeriatricians. Therefore, this narrative review critically examines the differential and overlapping neuroimaging features of chronic SCZ and AD to facilitate more accurate clinical assessment and diagnosis in late life.
Indexed as
Identifiers
42489907What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.